New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations

Could Product Succeed Where SGLT2 Inhibitors Failed?

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.